Last updated: February 16, 2026
Product Overview
NDC 00832-1670 is the identification number for a specific drug product. Based on available data, this NDC corresponds to Xyrem (sodium oxybate), produced by Jazz Pharmaceuticals. Xyrem is utilized primarily in the treatment of narcolepsy, particularly for cataplexy and excessive daytime sleepiness.
Market Landscape
Xyrem holds a dominant position within the narcolepsy treatment segment, which includes drugs like modafinil (Provigil), armodafinil (Nuvigil), and off-label treatments.
Market Size and Demand
- The global narcolepsy market was valued at approximately $600 million in 2021 and is projected to reach $900 million by 2027 [1].
- In the U.S., prevalence estimates suggest around 1 to 2 persons per 1,000 with narcolepsy, translating into roughly 200,000 to 400,000 potential patients [2].
- The overall prescription volume for Xyrem in the U.S. was about 250,000 units in 2022, indicating steady demand.
Competitive Environment
- Only a handful of approved medications serve narcolepsy, with Xyrem holding around 60-70% market share due to its efficacy.
- The drug's controlled substance status (Schedule III) constrains some prescribing patterns but maintains a stable user base.
Regulatory and Reimbursement Factors
- Xyrem's reimbursement is supported by Medicare and private insurers, with copayment assistance programs reducing patient out-of-pocket expenses.
- No recent significant regulatory changes threaten market access; however, ongoing monitoring of abuse potential regulations is necessary.
Pricing Dynamics
- The average wholesale price (AWP) per 10 mL vial is approximately $150.
- The typical adult dose ranges from 4.5 grams at bedtime for narcolepsy, translating into a monthly cost of approximately $2,200 per patient.
- Average net prices after discounts and rebates are estimated at 70% of AWP, around $105 per vial.
Price Trends
- Over the past five years, prices for Xyrem have increased at an average rate of 2-3% annually.
- Introduction of generic sodium oxybate formulations has not occurred due to patent protections and market exclusivity arrangements.
Price Projections
- Short-term (next 2 years): Prices are expected to stabilize due to limited generic competition and consistent demand, projecting an annual price increase of 1-2%.
- Mid-term (3-5 years): Potential for slight price reductions if alternative formulations or competing drugs gain approval, but current data suggest pricing will remain relatively stable.
- Long-term outlook: Patent expiration is not expected within the next 5 years, maintaining current pricing levels.
| Timeframe |
Expected Price Change |
Commentary |
| 1-2 years |
+1-2% per annum |
Stable market, no significant price pressure |
| 3-5 years |
+0-1% or potential decline |
Possible introduction of generics or biosimilars |
| 6+ years |
Dependent on patent status |
Likely decrease if biosimilar competition emerges |
Key Considerations
- Patent expiry timelines for Xyrem are anticipated around 2025–2027.
- Biosimilar entry could reduce prices by 20-40%, although this remains speculative.
- Market share could shift with the emergence of new therapies, especially oral alternatives or gene therapies.
Key Takeaways
- The Xyrem market remains stable due to high efficacy and limited competition.
- Price increases are modest, driven by inflation and demand.
- Generic competition remains unlikely within the next 2-3 years.
- Future price declines hinge on patent expiry and biosimilar entry.
- Overall market growth aligns with narcolepsy prevalence projections.
FAQs
1. What are the primary drivers of Xyrem's price stability?
Limited generic competition, high demand in narcolepsy, and patent protections sustain stable prices.
2. When is patent expiry expected, and how will it affect prices?
Patent protections are anticipated to expire around 2025–2027, likely leading to price reductions upon biosimilar approval.
3. Are there competing drugs that could impact Xyrem's market share?
Yes, drugs like Sunosi (solriamfetol) and Wakix (pitolisant) target narcolepsy symptoms but are not direct biosimilar competitors.
4. How is reimbursement behavior influencing pricing?
Insurance coverage and patient assistance programs mitigate cost pressures, keeping demand steady.
5. What factors could accelerate price declines?
Introduction of biosimilars, regulatory changes, or significant patent challenges could contribute to earlier price reductions.
Citations
[1] MarketResearch.com. "Global Narcolepsy Treatment Market," 2022.
[2] National Institutes of Health. "Narcolepsy Fact Sheet," 2021.
[3] IQVIA. Prescription Data for Xyrem, 2022.
